Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
株式のランク #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
株価
$0.04959193
最終同期: 2025-03-17
時価総額
$79.94M
変化(1日)
13.49%
変化(1年)
0.00%
SE
取引 Abliva AB (publ) (ABLI)

カテゴリー

Abliva AB (publ)(ABLI)の収益
Aug 2026 時点の収益 TTM: 0
Abliva AB (publ) の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Abliva AB (publ) の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH